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Consensus guidelines have consistently identified elevated low-density lipoprotein cholesterol (LDL-C) levels as the primary 
lipid target for the treatment of patients at high risk for developing 
coronary heart disease (CHD) (1,2). At present, 3-hydroxyl-3-methyl-
glutaryl CoA reductase inhibitors (statins) are the gold standard for 
lipid-modifying therapy (LMT) due to their efficacy in reducing 
LDL-C levels, ability to reduce CHD risk and excellent safety profile 
(1,2). Despite the clear benefit of lowering LDL-C levels through the 
use of statins, many patients are still at substantial risk of CHD events 
(3). To help address this residual risk, there has been a renewed 
emphasis on low high-density lipoprotein cholesterol (HDL-C) levels 
and elevated triglyceride (TG) levels as modifiable risk factors (1,2). 
Epidemiological studies have shown that the levels of both HDL-C 
and TG are strong predictors of cardiovascular events (4,5). In addi-
tion, clinical trials have demonstrated a reduction in CHD risk with 
other LMTs, such as niacin and fibrates, which have beneficial effects 
on the multiple lipid abnormalities that characterize mixed dyslipi-
demia (6,7). As a result, current guidelines have begun to recommend 
the inclusion of other LMTs, in addition to statin therapy, for high-risk 
patients with mixed dyslipidemia (1,2,8).
Although clinical guidelines have stressed the importance of rec-
ognizing and treating mixed dyslipidemia, studies have shown that not 
all patients achieve recommended lipid levels in regular clinical prac-
tice. A longitudinal study using data from a United States health 
maintenance organization found that LMT significantly improved 
LDL-C goal attainment; however, nearly 50% of patients did not 
achieve recommended levels of HDL-C and 24% of patients con-
tinued to exhibit mixed dyslipidemia (9). A recent review of a 
Veterans’ Affairs Hospital Network of CHD patients in the United 
States revealed that while 80% of patients achieved LDL-C target 
levels, only 51% of inidviduals with elevated TG levels achieved both 
LDL-C and non-HDL-C goals (10). Additional studies conducted in 
Europe demonstrated that the prevalence of mixed dyslipidemia 
among patients primarily treated with statins was as high as 30% to 
40% (11,12).
In contrast, few studies have explored the attainment of recom-
mended lipid levels among Australian patients treated with LMT. 
Results of the Bettering the Evaluation and Care of Health (BEACH) 
study, a national cross-sectional survey of general practices in Australia, 
showed that only 62% of individuals who were prescribed statins 
achieved target LDL-C levels (13). Similarly, the Australian Diabetes, 
Obesity and Lifestyles Study (AusDiab), conducted among individuals 
with type 2 diabetes mellitus (T2DM) treated in general practices in 
1999 and 2000, found that 71% of patients treated with LMT achieved 
target total cholesterol (TC) levels (≤5.5 mmol/L) (14). The objective 
of the present study was to determine the prevalence of elevated TG, 
low HDL-C and elevated LDL-C levels among Australian patients in 
regular clinical practice and to evaluate the attainment of recom-
mended lipid levels following LMT. In addition, the study sought to 
characterize the predictors of attainment of LDL-C goal levels and 
recommended TG levels after LMT initiation. 
METHODS
Study sample
The present longitudinal study of Australian patients undergoing LMT 
in regular clinical practice is a subset of the Prevalence, Treatment 
Patterns & Resource Use in Patients with Mixed Dyslipidemia Using 
Lipid Lowering Agents (PRIMULA) study performed in 14 countries 
worldwide. Patients undergoing LMT for at least one year and up to 
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BACkgrOunD: Few studies have assessed the prevalence of mixed 
dyslipidemia (MD) and the effectiveness of lipid-modifying therapy (LMT) 
for the treatment of abnormal levels of low-density lipoprotein cholesterol 
(LDL-C), triglycerides (TG) and high-density lipoprotein cholesterol 
(HDL-C) in Australian clinical practice. 
OBjECTiVE: To estimate the prevalence of MD in Australian patients 
undergoing LMT.
METHODS: Patients 35 years of age and older undergoing LMT for 
≥1 year were enrolled from nine general practice and cardiologist/
endocrinologist outpatient clinics in Australia between April 2007 and 
May 2008. Lipid levels, including LDL-C, HDL-C and TG levels, were 
prospectively collected at the enrollment date and from patient records 
one year before LMT was initiated. Normal lipid levels were assessed 
according to Australian guidelines. Multivariate logistic regression was 
used to evaluate predictors of normal lipid level attainment.
rESulTS: Of 297 patients (mean age 60.1 years; 43% male), the preva-
lence of MD before LMT was 61%; 93% of patients had elevated LDL-C 
levels, 17% had low HDL-C levels and 62% had elevated TG levels. 
Following LMT (98.3% statins), 31% of patients had MD. The prevalence 
of elevated LDL-C levels, low HDL-C levels and elevated TG levels were 
44%, 21% and 42%, respectively. Baseline lipid levels were significant 
predictors of attainment of normal LDL-C levels (OR 0.42 [95% CI 0.27 to 
0.63]) and TG levels (OR 0.26 [95% CI 0.16 to 0.45]).
COnCluSiOn: Among Australian patients primarily treated with sta-
tins, nearly one-third had MD despite LMT. LMT considerably improved 
LDL-C goal attainment; however, a large proportion of patients did not 
achieve normal HDL-C and TG levels. Patients may benefit from a more 
comprehensive approach to lipid management that treats all three lipid 
risk factors, as suggested in clinical guidelines. 
key Words: Australia; Dyslipidemia; High-density lipoprotein cholesterol; Lipid 
modifying therapy; Low-density lipoprotein cholesterol; Triglycerides 
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two years were enrolled from nine different Australian general prac-
tice and cardiologist/endocrinologist outpatient clinics between April 
2007 and May 2008. The study protocol was approved by the Bellberry 
Human Research Ethics Committee (Dulwich, Australia), the Monash 
University Standing Committee on Ethics in Research Involving 
Humans (Melbourne, Australia) and the South Eastern Sydney and 
Illowarra Area Health Service – Northern Network Human Research 
Ethics Committee (Sydney, Australia). Written informed consent was 
obtained from all study participants.
On the date of enrollment, participants were asked to complete a 
short questionnaire to provide details on clinical risk factors and char-
acteristics (Figure 1). In addition, a fasting blood sample was drawn 
from each patient to conduct a complete lipid profile, including levels 
of TC, LDL-C, HDL-C and TG. Physicians or trained medical record 
reviewers reviewed patient medical records to obtain detailed clinical 
information. An index period was defined, from April 2005 to 
May 2007, during which patients received the initial prescription for 
an LMT, consisting of statins, ezetimibe, fibrates, niacin, bile acid 
sequestrants, omega-3 triglycerides or cholesterol absorption inhibit-
ors. Patient demographics, clinical characteristics and previous fasting 
lipid profiles were collected one year before the index date (baseline). 
Data collected through the enrollment questionnaire was used to sup-
plement information not found in patient medical records.
All patients initially selected on the enrollment date were screened 
based on several inclusion/exclusion criteria. Only patients 35 years of 
age and older on the enrollment date were included. Patients were 
required to have complete lipid panel data within one to two years 
before the index date and to have been continuously treated with an 
LMT from the index date until at least six weeks before the enrollment 
date. Treatment gaps of up to six weeks were permitted after LMT initia-
tion, except for the first six weeks following the index date. In addition, 
patients were included if their medical record contained complete infor-
mation on cardiovascular risk factors and conditions during the baseline 
period. Patients who were not willing to provide informed consent and 
undergo a lipid test and/or were participating in any clinical trial or study 
involving a therapeutic intervention at enrollment were excluded. 
Finally, to ensure accurate treatment information, patients who switched 
LMTs at any point after the index date were excluded. 
A total of 350 patients, 35 years of age and older, who were under-
going LMT were identified at enrollment and agreed to participate in 
the present study. Of these patients, 26 had missing or incomplete lipid 
panel data at baseline or follow-up and were, therefore, excluded. An 
additional 12 patients were excluded because the latest available base-
line lipid data were recorded less than 12 months before the index 
date. Finally, 15 patients who switched LMTs at any point after the 
index date were excluded. As a result, 297 patients met the study 
inclusion criteria.
Patient lipid profiles were obtained using the fasting blood sample 
provided during enrollment and were retrieved from laboratory records 
(fasting or nonfasting) during the baseline period. TG and HDL-C 
levels were measured using enzymatic assays, whereas the LDL-C level 
was calculated using the Friedewald formula (15):
LDL-C = TC − HDL-C − 0.45 × TG
LDL-C values calculated using the Friedewald formula were con-
sidered to be invalid if the TG value was >4.5 mmol/L, in which case 
the LDL-C levels were measured directly using homogenous assays in 
a total of six patients. If a patient had multiple lipid tests conducted 
during the baseline period, only the values measured closest to the 
index date were extracted. Lipid goals and recommended levels were 
defined according to the 2005 National Heart Foundation of Australia/
Cardiac Society of Australia and New Zealand guidelines for lipid 
management (1). Briefly, the target level for LDL-C was <2.0 mmol/L 
for patients with established CHD and <2.5 mmol/L for patients with-
out CHD. Recommended HDL-C levels were considered to be 
>1.0 mmol/L and >1.3 mmol/L for men and women, respectively, and 
recommended TG levels were <2.0 mmol/L.
Additional relevant patient demographics, risk factors/conditions, 
medications and family history were also collected during the baseline 
period. Systolic and diastolic blood pressure values were based on the 
mean values recorded at all physician visits during the baseline period. 
A diagnosis of hypertension was defined as blood pressure 
≥140/90 mmHg or a prescription for antihypertensive medications at 
baseline. Smoking status (current smoker, past smoker, nonsmoker) 
and family history of cardiovascular disease (CVD) or T2DM were 
defined based on the most recent recorded data before the index date 
or patient response from the enrollment questionnaire. If no data were 
recorded in the patient history or enrollment questionnaire, the 
patient was assumed to be a nonsmoker and to have no history of CVD 
or T2DM. 
Patients who were at high risk for CHD were also defined based on 
eligibility criteria for LMT treatment defined by the Australian 
Pharmaceutical Benefits Scheme, a division of the Department of 
Health and Aging that provides details on medicines subsidized by the 
Australian Government (16). These included patients with estab-
lished CVD and T2DM. Diagnoses of CVD were based on the occur-
rence of myocardial infarction, unstable angina, coronary artery 
procedures (angioplasty or bypass surgery) or stroke in the medical 
record. T2DM was identified based on clinical diagnosis or prescrip-
tions for diabetes medications. 
Data analyses
Descriptive analyses were used to compare the proportion of patients 
who achieved LDL-C goal levels and recommended HDL-C and TG 
levels both before and after LMT initiation. Additional descriptive 
statistics for all patient characteristics at baseline were also performed. 
Multivariate analyses, using multivariate logistic regression, were con-
ducted to determine the clinical predictors of attaining LDL-C goals 
and recommended TG and HDL-C levels at follow-up. All analyses 
were performed using SAS version 8.2 (SAS Institute Inc, USA). 
Statistical analyses were considered to be significant at P<0.05 and if 
the 95% CI of the OR did not include 1.0.
rESulTS
The study sample included a total of 297 patients (mean age 60.1 years; 
43.1% male) who met the study inclusion criteria (Table 1). The 
majority of patients were hypertensive (n=215, 72.4%), and 12.5% 
and 27.3% of patients had previous diagnoses of CVD and T2DM, 
respectively. In addition, most patients were prescribed at least one 
medication for conditions other than dyslipidemia (86.9%, mean 
[± SD] 3.6±2.5 prescriptions). At the index date, nearly all patients 
were treated with statin monotherapy (92.9%), while a small minority 
also received omega-3 fatty acids (4.7%) or fibrates (0.3%) in com-
bination with a statin (Table 2). Among patients who received statins, 
most were prescribed atorvastatin (66.3%), at a dose of 20 mg (26.8%) 
or 40 mg (23.0%), and 18.9% were prescribed simvastatin. 
Before therapy, elevated LDL-C levels were common, present in 
91.4% and 93.5% of all male and female patients, respectively (Figure 2). 
In addition, 68.0% of male and 57.4% of female patients had elevated 
TG levels, whereas 28.1% of male and 23.1% of female patients had low 
HDL-C levels. Nearly two-thirds of the study sample (61.4%) had mixed 
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dyslipidemia, characterized by ≥2 lipid abnormalities. Following therapy, 
the proportion of patients who had not reached the LDL-C goal level 
decreased substantially to 45.3% and 43.8% of all male and female 
patients, respectively. Conversely, the proportion of patients with low 
levels of HDL-C increased slightly (35.9% of male and 27.2% of female 
patients) and elevated TG levels persisted among 46.1% and 39.6% of 
all male and female patients, respectively. In addition, approximately 
30.8% of patients continued to exhibit mixed dyslipidemia. 
The results of multivariate analyses to determine factors associated 
with LDL-C goal level attainment and recommended TG level attain-
ment are presented in Table 3. Analyses to assess factors associated with 
attainment of recommended levels of HDL-C were also performed. 
However, because only a small number of patients did not attain the 
recommended HDL-C levels, the validity of the model results were ques-
tionable and were, therefore, not reported. After controlling for age, sex, 
number of days of therapy and relevant cardiovascular risk factors, base-
line levels of LDL-C and TG were the strongest negative predictors of 
recommended lipid level attainment (P<0.0001). A 1 mmol/L increase 
in LDL-C at baseline was associated with a 58% decrease in the odds of 
achieving target LDL-C levels (OR 0.42 [95% CI 0.27 to 0.63]), whereas 
a 1 mmol/L increase in baseline TG levels was associated with a 74% 
decrease in the odds of achieving recommended TG levels at follow-up 
(OR 0.26 [95% CI 0.16 to 0.45]). Sex was also significantly associated 
with LDL-C goal attainment (OR 2.28 [95% CI 1.05 to 4.95]; P<0.05). 
All other factors did not produce statistically significant results.
DiSCuSSiOn
The results of the present observational cohort study involving 
patients from Australian general practices suggest that LMT, primarily 
using statins, substantially improved the proportion of patients who 
achieved guideline-recommended target LDL-C levels. Conversely, 
over 40% of patients continued to have elevated TG levels, and low 
HDL-C levels persisted in more than one-quarter of patients. 
Furthermore, nearly one-third of patients (31%) had mixed dyslipi-
demia despite LMT.
Attainment of recommended lipid levels was consistently lower 
among men than among women. In particular, men had a higher preva-
lence of elevated LDL-C than women, despite LMT. Similarly, multi-
variate analyses revealed that, among women, the likelihood of attaining 
the LDL-C goal level following therapy was over twice that among men 
(OR 2.28 [95% CI 1.05 to 4.95]; P=0.04). Further research should inves-
tigate whether these sex-specific differences in LDL-C goal attainment 
are a result of biological or possible dietary or behavioral differences, 
which may impact the effectiveness of LDL-C-lowering therapy. 
The results of the present study are largely consistent with those of 
cross-sectional studies conducted in United States and European clin-
ical settings that analyzed multiple recommended lipid level attain-
ment among patients who did and did not undergo LMT (11,12,17). 
Although these studies also found a high prevalence of mixed dyslipi-
demia, ranging from 30% to 40%, their cross-sectional design made it 
difficult to determine the extent to which LMT was associated with 
changes in lipid profiles among the patients studied. Conversely, a 
recent retrospective longitudinal study of patients in general practice 
in the United States also found that therapy, primarily using statins 
(96%), notably decreased the percentage of patients who did not 
achieve LDL-C targets from 77% to 22%; however, 24% of patients 
continued to exhibit multiple dyslipidemia (9). The present study sug-
gests that the management of mixed dyslipidemia is also a persistent 
challenge in Australian clinical practice. 
Previous research has demonstrated that the magnitude of the 
reduction of cardiovascular events achieved through the use of statins 
is directly proportional to the level of LDL-C reduction, with further 
benefit achieved from more intensive statin therapy (3). Consistent 
with this observation, clinical guidelines recommend higher statin 
dosages (eg, 80 mg simvastatin or atorvastatin daily) or more potent 
statins (eg, 20 mg rosuvastatin daily) to achieve these benefits (1,2). 
In the present study, however, the majority of patients taking statins 
were prescribed atorvastatin at a dose of 20 mg or 40 mg. Therefore, a 
number of patients treated with statins in Australia may benefit from 
more intensive statin therapy to better achieve target LDL-C levels 
and ultimately reduce CHD risk. 
Despite the clear benefit of lowering LDL-C levels through the use 
of statins, many patients are still at substantial risk of CHD events (3). 
To help reduce this residual risk, studies have shown that other LMTs, 
which target multiple lipid abnormalities, provide additional benefits 
beyond statin monotherapy. Niacin is considered to be the most effect-
ive HDL-C modifying agent available, with increases in HDL-C levels of 
up to 20% to 30% and reductions in TG levels of up to 20% to 50% (7), 
TAble 1
baseline characteristics of patients initiated on lipid-
modifying therapy
Patient characteristics All patients (n=297)
Age, years, mean ± SD 60.1±10.4
Male sex 43.1
Cardiovascular risk factors
   Current smoker 9.4
   Previous cardiovascular disease* 12.5
   Type 2 diabetes mellitus† 27.3
   Family history of coronary heart disease 16.7
   Family history of type 2 diabetes mellitus 26.7
   Hypertension diagnosis or medication 72.4
Systolic blood pressure, mmHg, mean ± SD 134.3±15.0
Other medications‡ 86.9
   Number of medications, mean ± SD 3.6±2.5
Data presented as % unless otherwise indicated. *Patients with established 
cardiovascular disease (coronary heart disease or cerebrovascular disease); 
†Patients with diagnosis or prescriptions for type 2 diabetes mellitus; ‡Patients 
who were prescribed at least one medications for conditions other than dys-
lipidemia. 
TAble 2
lipid-modifying therapies for all patients at the index date
lipid-modifying therapy* Percentage of all patients (n=297)
Monotherapy
   Statins 92.9
   Fibrates 1.7
Combination therapy
   Statin and fibrate 0.3
   Statin and omega-3 fatty acid 4.7
   Statin and other 0.3
Statin dose†
   Atorvastatin 66.3
      <20 mg 12.4
      20 mg 26.8
      40 mg 23.0
      ≥60 mg 4.1
   Simvastatin 18.9
      <20 mg 0.0
      20 mg 7.2
      40 mg 10.0
      ≥60 mg 1.7
   Other 14.8
      <20 mg 6.2
      20 mg 4.8
      40 mg 3.1
      ≥60 mg 0.7
*There were no identified patients on lipid-modifying therapy with ezetimibe, 
niacin, bile acid sequestrants or cholesterol absorption inhibitors. †For patients 
on statin mono- or combination therapy, reflects the highest statin dose from 
statin initiation (index date) through follow-up
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although long-term adherence has been impaired by tolerability issues 
associated with flushing (18). Recent clinical trials of extended-release 
niacin combined with laropiprant, a compound shown to reduce flush-
ing, have demonstrated substantial improvements in tolerability with 
similar efficacy compared with other formulations of extended-release 
niacin (19). When used alone or in combination with statins, niacin 
has also been associated with a significant reduction in cardiovascular 
events (20,21). Conversely, the Atherothrombosis Intervention in 
Metabolic syndrome with low HDL/high triglycerides: Impact on Global 
Health outcomes (AIM-HIGH) trial of niacin in combination with 
statins with or without ezetimibe in patients at target LDL-C levels was 
stopped prematurely by the National Institute of Health on grounds of 
futility, creating doubt regarding the usefulness of niacin for the reduc-
tion of residual risk (22).
Similarly, fibrates are associated with a 10% to 20% increase in 
HDL-C levels and a 20% to 50% reduction in TG (6,7), although 
recent trial evidence suggests that cardiovascular event reductions are 
confined to patients with baseline TG levels >2.0 mmol/L (23). The 
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial 
demonstrated that fenofibrate combined with statin treatment was not 
TAble 3
Multivariate predictors of lipid goal or recommended lipid level attainment at follow-up (n=155)* 
lDl-C Triglycerides
Patient characteristic OR (95% CI) P OR (95% CI) P
Age 1.00 (0.96–1.04) 0.93 1.00 (0.96–1.05) 0.93
Female sex 2.28 (1.05–4.95) 0.04† 0.86 (0.34–2.18) 0.74
Current smoker 1.21 (0.38–3.89) 0.74 2.34 (0.57–9.71) 0.24
Previous CVD 0.46 (0.14–1.47) 0.19 0.37 (0.11–1.27) 0.11
Previous T2DM 1.89 (0.75–4.63) 0.18 0.95 (0.36–2.56) 0.92
Family history of CHD 0.77 (0.25–2.36) 0.65 1.80 (0.40–8.18) 0.45
Family history of T2DM 1.26 (0.53–3.00) 0.58 0.68 (0.25–1.84) 0.45
Hypertension 1.04 (0.37–2.96) 0.94 0.73 (0.18–3.00) 0.66
Days of therapy 1.01 (0.73–1.38) 0.98 0.85 (0.58–1.24)  0.40
Baseline LDL-C, mmol/L 0.42 (0.27–0.63) <0.0001† – –
Baseline triglycerides, mmol/L – – 0.26 (0.16–0.45) <0.0001†
*Only a small number of patients did not attain normal high-density lipoprotein cholesterol levels; thus, multivariate analyses for the attainment of normal HDL-C 
levels were not reported. †Significant at α<0.05 level. CHD Coronary heart disease; CVD Cardiovascular disease; LDL-C Low-density lipoprotein cholesterol; T2DM 
Type 2 diabetes mellitus; TG Triglycerides
Figure 2) A Prevalence of dyslipidemias in male patients before and after lipid-modifying therapy (n=128). B Prevalence of dyslipidemias in female patients 
before and after lipid-modifying therapy (n=169). HDL-C High-density lipoprotein cholesterol; LDL-C Low-density lipoprotein cholesterol; TG Triglycerides
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only safe, but also decreased cardiovascular events by 30% compared 
with statin treatment alone among diabetic patients with baseline TG 
levels >2.0 mmol/L (23). Another effective therapy in patients with 
elevated TG levels are long-chain omega-3 fatty acids, which have a 
similar efficacy to fibrates and negligible side effects (24).
Given the high prevalence of mixed dyslipidemia despite the use of 
statins among Australian patients included in the present study, com-
bination therapy using alternative LMTs, such as niacin, fibrates or 
omega-3 fatty acids, in addition to statins could be advantageous for 
these patients. The present study also found that, controlling for other 
risk factors, patients with higher baseline levels of LDL-C and TG are 
less likely to achieve recommended lipid levels following LMT. Therefore, 
these results further suggest that more comprehensive approaches to 
lipid management are needed to effectively treat these patients.
Although the present study provides valuable insights into the 
impact of LMT on the management of mixed dyslipidemia among 
Australian patients in general practice, it has certain limitations. As in 
other analyses using data from patient medical records, prescriptions 
for LMTs are only recorded by physician order in the medication list. 
As a result, the data may not fully capture actual drug use patterns. In 
addition, the study analyses focused exclusively on adherent patients 
who maintained therapy for at least one year before study enrollment 
and had a complete baseline lipid profile. A previous survey of adher-
ence to LMT in Australia suggests that approximately 25% of patients 
are noncompliant with therapy, which can lead to adverse health out-
comes and increased costs of health care (25). Therefore, the study 
results may represent a more optimistic portrayal of recommended 
lipid level attainment in regular clinical practice. In addition, the 
resultant smaller sample of adherent patients may have restricted the 
ability of the multivariate analyses to identify independent predictors 
of lipid goal attainment. Finally, because the study data was mainly 
obtained from a review of patient medical records, information on 
ethnic, professional and social background could not be obtained. As 
a result, the potential for residual confounding due to behavioral and 
environmental factors that may also independently affect patient lipid 
levels, such as diet, exercise and income, cannot be discounted. 
Further analyses should investigate whether differences in cultural and 
socioeconomic factors may give rise to disparities in the attainment of 
goal/normal lipid levels across different ethnic groups in Australia.
COnCluSiOn
The results of the present study demonstrate that lipid management in 
Australia, which largely consists of statin monotherapy, considerably 
improved LDL-C goal attainment. However, a large proportion of 
patients do not achieve recommended levels of HDL-C and TG, and 
nearly one-third continue to have mixed dyslipidemia. Therefore, 
patients could benefit from a more comprehensive approach to lipid 
management that treats all three lipid risk factors with specific emphasis 
on the attainment of LDL-C goal levels and recommended TG levels. 
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